Merck has partnered with company builder mantro GmbH to launch EdiMembre, a deep-tech spinout that will commercialize Merck's ...

Merck shares have dropped by around a third since the start of July 2024, amid investor worries over how the company will ...

Merck’s strong oncology gains, 4% yield, and low PEG ratio support its value case despite sector risks and patent concerns.

Merck KGaA has swooped into a neurological-focused pact with RNA biotech Skyhawk Therapeutics that could top out at $2 ...

Merck & Co (NYSE: MRK) and Daiichi Sankyo (TYO: 4568) have received Breakthrough Therapy designation from the US regulator ...

Merck KGaA agreed to collaborate with Skyhawk Therapeutics Inc. to develop neurological therapies in a deal that could be ...

Rahway: Merck and Daiichi Sankyo have announced that Ifinatamab deruxtecan (I-DXd) has been granted Breakthrough Therapy ...

The European Commission has granted German pharmaceutical giant Merck approval to use the cancer drug Ogsiveo, the ...

Waltham, Massachusetts–based Skyhawk Therapeutics has been collecting collaborations with larger companies in spades since ...

Merck has begun the 8% reduction of its workforce—an initiative that the company revealed two weeks ago—with the dismissal of ...

Pfizer is a solid dividend stock. Its forward yield currently tops 7%, and the company has increased its payouts by 19.5% in ...

German drugmaker Merck KGaA on Thursday joined peers in saying it was considering distribution models that serve U.S.